Применение статинов при ишемическом и реперфузионном повреждении сердца

2021 ◽  
Vol 84 (12) ◽  
pp. 39-44
Author(s):  
Андрей Владимирович Крылатов ◽  
Ольга Евгеньевна Ваизова ◽  
Светлана Васильевна Позднякова ◽  
Анастасия Павловна Зима ◽  
Ирина Викторовна Петрова ◽  
...  
Keyword(s):  
No Reflow

Статины способствуют повышению толерантности сердца к действию ишемии/реперфузии. Статины вызывают уменьшение размера инфаркта, оказывают антиаритмический эффект, обеспечивают восстановление сократимости сердца во время реперфузии, предупреждают возникновение феномена no-reflow. Статины препятствуют постинфарктному ремоделированию сердца. Установлено, что кардиопротекторный эффект статинов не зависит от уровня холестерина в крови. В инфаркт-лимитирующем эффекте статинов участвует NO-синтаза, PI3-киназа, Akt-киназа, протеинкиназа С и митоКАТФ-каналы. Применение статинов в больших дозах не оказывает кардиопротекторного эффекта у пациентов с коронарным шунтированием или острым инфарктом миокарда. Приём сатинов улучшает отдалённый прогноз у пациентов, перенесших острый инфаркт миокарда.

Microscopic Observation of FiltrapTM Membrane in Filter Slow Flow/No Reflow Phenomenon

2016 ◽  
Vol 8 (2) ◽  
pp. 98-103
Author(s):  
Akifumi Higashi ◽  
Mitsuru Kimura ◽  
Tatsuya Hondo ◽  
Shin Eno ◽  
Keiji Matsuda ◽  
...  
Keyword(s):  
Microscopic Observation ◽  
Slow Flow ◽  
No Reflow ◽  
No Reflow Phenomenon

The influence of adenosine on the no-reflow phenomenon in anoxic and ischaemic hearts

Pathology ◽  
1982 ◽  
Vol 14 (2) ◽  
pp. 129-133 ◽  
Author(s):  
Stuart M. Humphrey ◽  
R.N. Seelye ◽  
J.B. Gavin
Keyword(s):  
No Reflow ◽  
No Reflow Phenomenon

Is Atherothromboaspiration a Possible Solution for the Prevention of No-Reflow Phenomenon in Acute Coronary Syndromes? Single Centre Experience and Review of the Literature

2019 ◽  
Vol 17 (2) ◽  
pp. 164-179
Author(s):  
Antonis S. Manolis
Keyword(s):  
Coronary Intervention ◽  
Covered Stent ◽  
Current Status ◽  
Extensive Literature ◽  
Review Of The Literature ◽  
Single Centre ◽  
Total N ◽  
No Reflow ◽  
Clinical Benefits ◽  
Meta Analyses

Background: Intracoronary thrombus in acute Myocardial Infarction (MI) confers higher rates of no-reflow with attendant adverse consequences. Earlier Randomized-Controlled-Trials (RCTs) of routine thromboaspiration during Percutaneous Coronary Intervention (PCI) indicated a clinical benefit, but more recent RCTs were negative. However, data of selective use of this adjunctive approach remain scarce. </P><P> Objective: The aim of this single-centre prospective study was to report the results of selective thromboaspiration during PCI in patients with intracoronary thrombi, and also to provide an extensive literature review on current status of thromboaspiration. </P><P> Methods: The study included 90 patients (77 men; aged 59.3±12.7 years) presenting with acute MI (STElevation MI (STEMI) in 74, non-STEMI in 16) who had intracoronary thrombi and were submitted to thromboaspiration. </P><P> Results: Total (n=67) or subtotal (n=18) vessel occlusions were present in 85 (94%) patients. Thromboaspiration and subsequent PCI were successful in 89/90 (98.9%) patients, with coronary stenting in 86 (96.6%). In 4 patients with residual thrombus, a mesh-covered stent was implanted. IIb/IIIa-inhibitors were administered in 57 (63.3%) patients. No-reflow occurred in only 1 (1.1%) patient. The postprocedural course was uneventful. Review of the literature revealed several early observational and RCTs and meta-analyses favouring manual, not mechanical, thrombectomy. However, newer RCTs and meta-analyses significantly curtailed the initial enthusiasm for the clinical benefits of routine use of thromboaspiration. </P><P> Conclusion: Selective thromboaspiration for angiographically visible thrombi in MI patients undergoing PCI, as an adjunct to mechanical reperfusion and to IIb/IIIa-inhibitors, may be an option since this manoeuvre may improve procedural and clinical outcome.

Intracoronary Injection of Drugs to Treat No – Reflow Phenomenon and Microcirculatory Dysfunction

2013 ◽  
Vol 11 (2) ◽  
pp. 84-88
Author(s):  
Andrea Rognoni ◽  
Alessandro Lupi ◽  
Chiara Cavallino ◽  
Gioel Gabrio Secco ◽  
Roberta Rosso ◽  
...  
Keyword(s):  
Microcirculatory Dysfunction ◽  
Intracoronary Injection ◽  
No Reflow ◽  
No Reflow Phenomenon

Assessment of Admission Time Cell Blood Count (CBC) Parameters in Predicting Post-primary Percutaneous Coronary Intervention TIMI Frame Count in Patients with ST-segment Elevation Myocardial Infarction

2020 ◽  
Vol 20 (3) ◽  
pp. 191-197
Author(s):  
Hossein Vakili ◽  
Isa Khaheshi ◽  
Amirsina Sharifi ◽  
Negin Nickdoost ◽  
Mohammad H. Namazi ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Platelet Count ◽  
P Value ◽  
Primary Pci ◽  
Blood Samples ◽  
Timi Frame Count ◽  
Admission Time ◽  
No Reflow ◽  
Corrected Timi Frame Count ◽  
No Reflow Phenomenon

Objectives: In this study, we aimed to assess the value of admission time CBC parameters in predicting post-primary PCI corrected TIMI frame count. Background: Recent years have witnessed a large series of studies evaluating different laboratory variables to predict no-reflow phenomenon following primary PCI (PPCI) in patients with STEMI. However, a general agreement about the most reliable predictor of the no-reflow phenomenon is challenging and also intriguing. Methods: The current study concluded 208 consecutive patients who underwent primary PCI for ST-Elevation Myocardial Infarction (STEMI) from January 2014 to February 2016. Blood samples were obtained after taking ECG. Complete blood samples were collected and analyzed within 5 minutes from sampling. Post-PCI corrected Thrombolysis in Myocardial Infarction (TIMI) frame count was determined by one interventional cardiologist blinded to patients’ clinical data. The correlation between admission time blood parameters and post-primary PCI corrected TIMI frame count in patients with STEMI were assessed. Results: Corrected TIMI frame count was positively correlated with WBC count (R: 0.18, P-value: <0.01), neutrophil count (R: 0.34, P-value: <0.01), and platelet count (R: 0.23, P-value: <0.01) and negatively correlated with lymphocyte count (R: -0.2, P-value: <0.01). Multiple linear regression results demonstrated that corrected TIMI frame count was positively correlated with neutrophil count (P < 0·001) and platelet count (P < 0·001) and negatively correlated with lymphocyte count (p=0.004). Conclusion: High counts of WBC, neutrophil, and platelet and low count of lymphocyte may be predictors of no-reflow in STEMI patients undergoing PPCI. The clinical significance of such predictive parameters becomes clear as we consider the treatment approach in STEMI patients. Appropriate risk stratification leads to better treatment planning and allocation of resources.

scholarly journals The role of LR-TIMAP/PP1c complex in the occurrence and development of no-reflow

EBioMedicine ◽  
2021 ◽  
Vol 65 ◽  
pp. 103251
Author(s):  
Xiaoyu Quan ◽  
Xiucheng Liu ◽  
Xichun Qin ◽  
Yuzhuo Wang ◽  
Teng Sun ◽  
...  
Keyword(s):  
No Reflow
Sign in / Sign up

Export Citation Format

Share Document